Annovis Bio Inc (ANVS)
Annovis Bio, Inc. is a clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases in the United States. Its lead candidate, buntanetap, is being studied in phase 2/3 trials for Alzheimer’s disease, in phase 3 for Parkinson’s disease, and in phase 2 for Lewy body dementia. The company is also advancing ANVS405, which is in phase 2 and phase 3 clinical testing for traumatic brain injury and/or stroke, along with ANVS301, which completed a phase 1 trial in later-stage Alzheimer’s disease and dementia. Annovis Bio was incorporated in 2008 and is headquartered in Malvern, Pennsylvania. The listed security is common stock on the NYSE.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-ANVS
|
$1.77
|
1.3% Upside
|
Fair
|
$11
|
528.6% Upside
|
Bargain
|
Weak
|
—
|
—
|
—
|
0.0%
|
August 18, 2026
|
-1.8x
|
24.0x
|
—
|
71.896 M
|
60.655 M
|
0.0%
|
88.5%
|
-20.5
|
—
|
64.8%
|
